BMS transfers Japan pemirolast rights
This article was originally published in Scrip
Bristol-Myers Squibbhas agreed to divest Japanese manufacturing and marketing rights to the anti-allergic Pemilaston (pemirolast) to the domestic firm Alfresa Pharma. The two companies will begin joint promotional activities this month and the full transfer is due for completion next March. The change reflects a shift by BMS to other areas such as oncology, HIV and rheumatoid arthritis and an effort by Alfresa Pharma (part of the Alfresa pharmaceutical wholesaling group) to expand its existing allergy portfolio, the firms explained. Pemilaston is marketed in Japan in several adult and paediatric oral formulations and in ophthalmic form, for bronchial asthma, allergic rhinitis and conjunctivitis.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.